Research Progress on the Application of Dapagliflozin in the Treatment of Chronic Kidney Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Research Progress on the Application of Dapagliflozin in the Treatment of Chronic Kidney Disease

Published:2024 Issue:01 Volume:14 Page:2255-2260
ISSN:2161-8712
Container-title:Advances in Clinical Medicine
language:
Short-container-title:ACM

Author:

汪水发

Publisher

Hans Publishers

Reference33 articles.

1. In silico discovery of potential sodium–glucose cotransporter-2 inhibitors from natural products for treatment of heart failure via molecular docking and molecular dynamics simulation approach

2. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors

3. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

4. The SGLT2i-mediated regulation of cardiovascular and safety outcomes among patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials

5. 刘姗姗, 赵璨, 罗力亚. 达格列净治疗老年2型糖尿病并心力衰竭患者的临床疗效及其对心功能的影响[J]. 实用心脑肺血管病杂志, 2022, 30(3): 107-111.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3